A Multicenter, parallel-group, double-blind, placebo-controlled phase 3 study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson's disease patients with motor complications not well controlled on medical treatment

Trial Profile

A Multicenter, parallel-group, double-blind, placebo-controlled phase 3 study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson's disease patients with motor complications not well controlled on medical treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Apomorphine (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms TOLEDO
  • Sponsors Britannia Pharmaceuticals; STADA Arzneimittel
  • Most Recent Events

    • 15 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 03 Sep 2017 This trial has been completed in Austria (End date: 2017-06-09).
    • 22 Aug 2017 This trial has been completed in Germany (End date: 2017-06-09).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top